News
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
22 Apr 24
Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $18 Price Target
22 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Goldman Sachs Maintains Buy on Roivant Sciences, Raises Price Target to $18
3 Apr 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $18
3 Apr 24
News, Price Target, Analyst Ratings
Deutsche Bank Maintains Buy on Roivant Sciences, Raises Price Target to $15
3 Apr 24
News, Price Target, Analyst Ratings
Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study
2 Apr 24
Biotech, News, Health Care, Movers, Trading Ideas, General
10 Health Care Stocks Whale Activity In Today's Session
29 Mar 24
Options
Where Roivant Sciences Stands With Analysts
25 Mar 24
Analyst Ratings
Truist Securities Reiterates Buy on Roivant Sciences, Maintains $23 Price Target
25 Mar 24
News, Price Target, Reiteration, Analyst Ratings
5 Value Stocks In The Healthcare Sector
19 Feb 24
News
Wolfe Research Initiates Coverage On Roivant Sciences with Outperform Rating, Announces Price Target of $17
15 Feb 24
News, Price Target, Initiation, Analyst Ratings
The Analyst Landscape: 4 Takes On Roivant Sciences
14 Feb 24
Analyst Ratings
HC Wainwright & Co. Maintains Buy on Roivant Sciences, Lowers Price Target to $17
14 Feb 24
News, Price Target, Analyst Ratings
Roivant Sciences Q3 2024 Adj EPS $(0.21) Beats $(0.32) Estimate, Sales $37.14M Beat $32.79M Estimate
13 Feb 24
Earnings, Earnings Beats, News
Earnings Scheduled For February 13, 2024
13 Feb 24
Earnings
Roivant Sciences Earnings Preview
12 Feb 24
Earnings
Press releases
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
2 Apr 24
Health Care, Press Releases
Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
26 Mar 24
Press Releases
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
30 Jan 24
News, Press Releases